| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC0179 |
| Trial ID | NCT01892293 |
| Disease | Multiple Myeloma |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| HLA | HLA-A2*01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Terminated |
| Title | A Phase I/IIa, Open Label, Multiple Site Clinical Trial Evaluating the Safety and Activity of Engineered Autologous T Cells Expressing an Affinity-enhanced TCR Specific for NY-ESO-1 and LAGE-1 in Patients With Relapsed or Progressive Disease in Multiple Myeloma |
| Year | 2013 |
| Country | United States |
| Company sponsor | Adaptimmune |
| Other ID(s) | ADP-0011-002 |
| Cohort 1 | |||||||||||||
|
|||||||||||||